PRESS RELEASE

IMPEDIIMED ANNOUNCES ANOTHER MANAGED CARE CONTRACT

FOR L-DEX® TESTING ADVANCING US REIMBURSEMENT

ImpediMed Limited today announced another contract with a US managed care organisation for use of its L-Dex technology as an aid in the clinical assessment of lymphoedema in female breast cancer patients. Integrated Health Plan, (IHP), a Preferred Provider Organization (PPO), represents greater than 10 million members across the US.

Integrated Health Plan is a Nationwide PPO Network that is contracted with, in part, Anthem BCBS, Cigna, Humana, Concentra Managed Care, Coventry Health Care, Maxicare Health Plan, Mutual of America, Scott & White Health Plan, Oxford Health Plan, Great West, Health Plan Administrators, United and WellPoint. In addition, employer groups IHP is contracted with include AT&T, Bank of America, Boeing Corporation, Major League Baseball, U.S. Department of Defense, Ford Motor Company, General Electric, K Mart Corporation, Levi Strauss, Trump Organization and the U.S. Postal Service.

“It is gratifying to put in place another managed care contract. We are excited about the partnership with IHP, and look forward to marketing with them the L-Dex® test throughout their national network.” said Greg Brown, ImpediMed’s CEO. He went on to say, “With so many payers and delivery providers of US healthcare, each managed care contract and every coverage statement from an insurer, builds yet another brick in the wall for our target of achieving effective reimbursement for L-Dex® testing”.

Across the United States, ImpediMed is continuing discussions with a variety of managed care organisations, public and private health insurance providers and the provider networks contracted with to provide medical services. The Company sees other opportunities to provide reimbursement by working with PPO’s, Independent Physician Associations (IPA’s), Health Maintenance Organizations (HMO’s), medical groups and the major health insurance providers.

ENDS

For further information contact:

Greg Brown ImpediMed CEO
T: 61-7-3860-3700; Mobile/Cell: +61408281127
L-Dex® is a trademark of ImpediMed Limited.

“L-Dex® values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity”.

**About ImpediMed**

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.

For more information, visit. www.impedimed.com

**About US Managed Care**